Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial

Autor: Diener, H, Agosti, R, Allais, G, Bergmans, P, Bussone, G, Davies, B, Ertas, M, Lanteri Minet, M, Reuter, U, Del Río, MS, Schoenen, J, Schwalen, S, van Oene, J, TOPMAT MIG 303 Investigators Group, C. Lampl, T. Berger, J. Jacquy, L. Herroelen, P. Louis, J. Schoenen, I. Milanov, Z. Zahariev, S. Bozhinov, P. Dočekal, M. Grünermelová, G. Waberžinek, P. Tfelt Hansen, M. Groenbech Jensen, I. Tsiropoulos, R. Kirkeby, M. J. Rasmussen, D. Valade, H. Massiou, C. Sereni, A. Donnet, M. Lanteri Minet, C. Lucas, G. Mick, A. Pradalier, E. Guegan Massardier, H. C. Diener, S. Evers, U. Reuter, A. Straube, D. Mitsikostas, K. Karageorgiou, I. Milonas, G. Georgiadis, G. Gyula, Á. Judit, H. Péter, V. László, O. Hardiman, B. Sweeny, L. Grazzi, B. Colombo, G. Bruzzone, A. Quattrone, C. Benedetto, G. D'Andrea, P. Barbanti, R. De Simone, F. Valguarnera, M. A. Al Jumah, A. Al Tahan, I. Monstad, R. sj, R. Salvesen, LJ Stovner, H. Kwiecinski, W. Fryze, D. Pruchnik Wolinska, R. Motyl, W. Kozubsk, K. Ulatowska Blaszyk, A. Prusinski, L. Cunha, J. Pereira Monteiro, P. Esperança, A. Boyko, A. Skoromets, T. Pogačnik, T. Hojs Fabjan, M. Sánchez Del Río, R. Agosti, F. Donati, B. Tettenborn, M. Siccoli, A. Siva, M. Ertaş, M. Zarifoğlu, B. Davies, P. Davies, D. Bates, M. Fontebasso, P. Cleland, S. Lipscombe, A. Dowson, M. Lawden, S. McPhee, B. Calder, FERRARESE, CARLO

Publikováno v: The Lancet Neurology. 6:1054-1062

BACKGROUND: Use of preventive therapy for migraine is often recommended for only 6-9 months, but no randomised, placebo-controlled trials have investigated migraine frequency after the end of prophylaxis. We assessed the effects of discontinuation of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b22841f260663d94791b83518d646dfe
https://doi.org/10.1016/s1474-4422(07)70272-7